Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agilent Technologies

American Tower

Andersons

Alexandria Real Estate Equities

CubeSmart

Edison

Ensign Group

Essential Properties Realty Trust Inc

Four Corners Property Trust

Getty Realty

Innovative Industrial Properties

Invitation Homes

Lincoln Electric Hlds

McCormick

Nucor

Realty Income Corp

Quanta Services

Raymond James

Schwab US Dividend Equity ETF

SEI Investments

TFI International

Toro

U.S. Bancorp

York Water

24 dividend increases are expected next week, including Nucor's 50th annual dividend increase. Consistently increasing dividend payouts leads to better performance for companies.

24 Upcoming Dividend Increases, Including A New Dividend King, To Finish 2023

Haemonetics

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?

HAE vs. SYK: Which Stock Is the Better Value Option?

MAHWAH, N.J., USA , Dec. 18, 2023 /PRNewswire/ -- Stryker (NYSE: SYK), one of the world's leading medical technology companies, announced today that it has executed a binding offer to Menix to acquire SERF SAS, a France-based joint replacement company.

Stryker announces intent to acquire SERF SAS, enhancing its global joint replacement leadership

Kalamazoo, Michigan, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that after 15 years of distinguished service, Dr. Srikant Datar has notified the Company that he will not stand for re-election at Stryker's 2024 Annual Meeting of Shareholders, which is expected to be held on May 9, 2024.

Stryker announces Dr. Srikant Datar will retire from Board of Directors

Amgen

Broadcom

Mastercard

Zoetis

The company offers integrated products and value-added services for Account holders Merchants Financial institutions Businesses Governments Mastercard also provides value-added products and services comprising cyber and intelligence solutions for parties to transact and proprietary insights, drawing on the moral use of consumer and merchant data services.

5 Sizzling Wall Street ‘Strong Buy” Stocks Are Also Raising Their Dividends This Week

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

HAE vs. SYK: Which Stock Should Value Investors Buy Now?

Stryker boasts a 13.7% annual return, consistent dividends, and innovation-driven market dominance. Stryker's focus on Orthopaedics and Spine, coupled with a resilient financial position and strategic acquisitions, positions it for continued success. Despite a premium valuation, Stryker's strong balance sheet, 30-year dividend growth history, and low payout ratio make it an appealing long-term investment.

Why Stryker Is An Awesome Healthcare Compounder

Stryker Corporation (NYSE:SYK ) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 1:20 PM ET Company Participants Glenn Boehnlein - CFO Jason Beach - Head, IR Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Stryker this afternoon. We have Glenn Boehnlein, CFO; and Jason Beach, who heads Investor Relations.

Stryker Corporation (SYK) 6th Annual Evercore ISI HealthCONx Conference (Transcript)

The Bulgarian parliament on Thursday approved a $1.5 billion purchase of Stryker fighting vehicles from the United States to modernise the country's army and bring it in line with NATO standards, the BTA news agency reported.

Bulgarian parliament okays $1.5 billion purchase of Stryker fighting vehicles from US

Stryker stock tumbled Friday after sales of its hip and knee replacements came up short, stoking worries of pressure from weight-loss drugs.

Stryker Stock Dives As Weight-Loss Drugs Continue To Haunt Its Beat And Raise

Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.

Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result

Stryker Corporation (NYSE:SYK ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Jason Beach - VP, IR Glenn Boehnlein - VP & CFO Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Andrew Ranieri - Morgan Stanley Philip Chickering - Deutsche Bank Robert Marcus - JPMorgan Chase & Co. Danielle Antalffy - UBS Vijay Kumar - Evercore ISI Shagun Chadha - RBC Capital Markets Matthew O'Brien - Piper Sandler & Co. Ryan Zimmerman - BTIG Yang Li - UBS Richard Newitter - Leerink Partners Eric Anderson - TD Cowen Joanne Wuensch - Citigroup Travis Steed - Bank of America Merrill Lynch Operator Welcome to the Third Quarter 2023 Stryker Earnings Call. My name is Krista, and I'll be your operator for today's call.

Stryker Corporation (SYK) Q3 2023 Earnings Call Transcript

Stryker Corp on Thursday raised the lower end of its full-year profit forecast as the medtech company sees steady demand for its medical and surgical devices from a post-pandemic pick-up in volumes of surgical procedures at hospitals.

Stryker tightens profit forecast on steady demand for its medical devices

Kalamazoo, Michigan, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2023: Third Quarter Results Reported net sales increased 9.6% to $4.9 billion Organic net sales increased 9.2% Reported operating income margin of 19.0% Adjusted operating income margin (1) increased 110 bps to 23.4% Reported EPS decreased 15.9% to $1.80 Adjusted EPS (1) increased 16.0% to $2.46   Third Quarter Net Sales Growth Overview   Reported   Foreign Currency Exchange   Constant Currency   Acquisitions / Divestitures   Organic MedSurg and Neurotechnology         10.5         %           0.2         %           10.3         %           0.2         %           10.1         % Orthopaedics and Spine         8.4                     0.4                     8.0                     —                     8.0           Total         9.6         %           0.3         %           9.3         %           0.1         %           9.2         % "We delivered another quarter of strong organic sales growth and continued margin expansion," said Kevin A. Lobo, Chair and CEO.

Stryker reports third quarter 2023 operating results

Evaluate the expected performance of Stryker (SYK) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Stay Ahead of the Game With Stryker (SYK) Q3 Earnings: Wall Street's Insights on Key Metrics

Stryker's (SYK) third-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Stryker (SYK) to Report Q3 Earnings: Is a Beat in Store?

Kalamazoo, Michigan, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at the Kimpton EPIC Hotel in Miami, Florida.

Stryker to participate in the 6th Annual Evercore ISI HealthCONx Conference

Baxter

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or Stryker (SYK). But which of these two stocks is more attractive to value investors?

BAX vs. SYK: Which Stock Is the Better Value Option?

Stryker (SYK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stryker (SYK) Reports Next Week: Wall Street Expects Earnings Growth

Abbott Labs

Intuitive Surgical

Johnson & Johnson

Medtronic

Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength in their MedTech units.

The Value Deepens for Medtech Stocks: Reversal Imminent

Stryker's dividend is covered by both adjusted diluted EPS and free cash flow, which should bode well for future dividend growth. The company's dedication to research and development supports its strong operating fundamentals. Stryker's interest coverage was nearly 14 in the first half of 2023, which explains why it enjoys a BBB+ credit rating from S&P.

Stryker: Don't Buy This Dividend Champion (Yet)

Boston Scientific

Insulet

Zimmer Biomet Hlds

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.

5 Medical Product Stocks to Buy Amid Industry Recovery

LEESBURG, Va.--(BUSINESS WIRE)--The Q Guidance System with Spine Guidance Software has been used to deliver enhanced surgical planning and navigation in over 2,400 spinal cases.

Over 2,400 Surgical Cases Completed Using Stryker's Q Guidance System with Spine Guidance Software in First Year

Kalamazoo, Michigan, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will host an Investor Day on Wednesday, November 8, 2023, at 2:30 p.m. Eastern Time, in Mahwah, New Jersey.

Stryker to host investor day

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

News for Stryker Stock (SYK)